News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sarepta Therapeutics (Formerly known as AVI BioPharma, Inc.) (SRPT) Holds Its Breath as Feds Order Halt to Ebola Work


8/7/2012 7:41:44 AM

Just when Sarepta Therapeutics had some news to get excited about, the company now has to brace itself for what could be a pretty big setback. The Bothell, WA-based biotech company (NASDAQ: SRPT) said last month that its experimental RNA-based drug for Duchenne Muscular Dystrophy showed some encouraging signs of improving walking ability for boys in a small clinical trial, which caused its shares to more than double. But the company’s R&D efforts were dealt a blow late last week when the U.S. Department of Defense ordered it to stop working on a lucrative defense contract as the government assesses budgets, and whether to terminate the program.

Read at Xconomy
Read at Reuters

Related News

comments powered by Disqus
Xconomy
Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES